SpineJack System Postmarket Registry
Launched by STRYKER INSTRUMENTS · Mar 9, 2021
Trial Information
Current as of June 12, 2025
Completed
Keywords
ClinConnect Summary
The SpineJack System Registry will employ a prospective, multicenter, observational, consecutive enrollment design. The sample size for this Registry will include at least 400 patients treated for VCFs across approximately 10 sites. A total of 240 patients will be treated with the SpineJack system and 160 patients will be treated with other vertebral augmentation (VA) procedures, such as BKP or VP. Sites within the U.S. may include healthcare professionals (HCPs) that are surgeons, pain physicians and/or interventional radiologists.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. 18 years of age or older
- • 2. Understand and sign the informed consent form (as applicable)
- • 3. Exhibit no altered mental status or language barrier that may prevent completion of the patient reported outcome (PRO) surveys following the procedure.
- • 4. VCF diagnosis made and/or confirmed at participating site.
- Exclusion Criteria:
- • -
About Stryker Instruments
Stryker Instruments is a leading global medical technology company specializing in the development of innovative surgical instruments and solutions that enhance patient outcomes and improve surgical efficiency. With a commitment to advancing healthcare, Stryker Instruments focuses on delivering high-quality products across various specialties, including orthopedics, neurosurgery, and minimally invasive surgery. Through rigorous research and clinical trials, Stryker Instruments aims to drive medical advancements and support healthcare professionals in delivering exceptional patient care. Their dedication to innovation, safety, and efficacy positions them at the forefront of the medical device industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milwaukee, Wisconsin, United States
Bronx, New York, United States
Lebanon, New Hampshire, United States
New York, New York, United States
New York, New York, United States
Winston Salem, North Carolina, United States
Edmond, Oklahoma, United States
Lebanon, New Hampshire, United States
Edmond, Oklahoma, United States
San Diego, California, United States
Federal Way, Washington, United States
Puyallup, Washington, United States
Larkspur, California, United States
Encinitas, California, United States
Boise, Idaho, United States
Puyallup, Washington, United States
Lebanon, New Hampshire, United States
Stuart, Florida, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials